Sandwich, UK — 4 November 2026: Discovery Park, Kent’s science and innovation hub, has launched the eighth edition of its Discovery Spark accelerator programme, welcoming 10 startups to its campus in Sandwich.
The eighth cohort brings together 13 founders working across drug discovery, diagnostics, wound care, crop science and biotechnology. Startups were selected based on the need for their innovation, the uniqueness of their solution and the strength of their team. Throughout November, founders will attend specialist-led sessions in Kent and London focused on investor readiness. Topics…
The Budget on 28 October 2026, the first under the new Prime Minister and John Healey’s first as Chancellor, left the rates of R&D tax relief unchanged and announced two changes to how claims are made. Companies making R&D claims on or after 1 April 2027 will no longer have to submit a Claim Notification Form, and the Additional Information Form will be simplified from autumn 2027. Alongside the Budget, HM Treasury opened a consultation on simplifying the corporate tax rules, R&D relief among them.
As with any Budget, there will be winners and losers. For R&D tax relief, the…
Bidwells' Creative Places team has appointed Sue Foxley and Harry Blevins, strengthening its research capability and London science and technology leasing offer as the business continues to grow.
Sue will be joining the Creative Places team on a part-time basis, to focus on leading edge research and data trends in science and technology as well as providing valuable insight to clients on ecosystem strategy through Creative Places consultancy mandates. Sue will continue to lead the Research function across the Bidwells Group.
Harry will also join the Creative Places team on a full-time…
Peer-reviewed Viewpoint ‘Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials’ presents argument for measuring both lung function and fibrosis extent in antifibrotic trials
Evaluation of evidence from multiple studies positions fibrosis extent as the strongest candidate for a new defined structural imaging endpoint and for a staged FDA qualification programme
Cambridge, UK, 2 November 2026 – Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced…
Common Synapse has just published The Unprompted Patient Journey – Patient Intelligence Report 2026, bringing together 3,835 public patient, caregiver and clinician narratives from six studies across eight neuro-related conditions.
Read the report here:https://commonsynapse.com/case-studies/CommonSynapse_The_Unprompted_Patient_Journey_2026.pdf
How are organizations architecting functional Artificial Intelligence (AI) strategies that will shape the next phase of AI in Medical Affairs?
Earlier this year, Digital Science brought together Medical Affairs leaders to explore how they’re approaching AI, and why they need to embed sustainable AI capabilities in day-to-day workflows.
The conversation covered six key topics:
Building trust and driving user adoption
Managing the volume and quality of scientific insights
Bridging the gap and demonstrating ROI
Governance, safety and regulatory alignment
Systematic literature review and…
The keynote panel, taking place at Genesis on 10 December at 1 Wimpole Street, London will explore the above question; What do you think should feature in the conversation? As the final preparations take shape, themes include:
Perceived progress in unlocking domestic institutional capital (such as pension funds and insurance pools) to support later-stage (Series B and beyond) rounds, thus reducing the reliance on overseas venture capital that often forces early cross-border buyouts.
The potential for creative commercial structures such as co-development partnerships, regional…
The keynote panel, taking place at Genesis on 10 December at 1 Wimpole Street, London will explore the above question; What do you think should feature in the conversation? As the final preparations take shape, themes include:
Breakthroughs beyond traditional small molecules and standard biologics, such as advanced RNA therapeutics (SymphoRNA), spatial genomics, and three-dimensional genome architecture (Nucleome Therapeutics).
Exploring how targeting previously "undruggable" pathways or cellular mechanisms (such as aging/longevity biology via LinkGevity or targeted protein…
New RNA-based NGS panel helps to detect, analyse and track high-impact AML-associated fusion events across multiple timepoints.
Oxford, UK, October 2026.
OGT, a leading global provider of genomic research and diagnostic solutions, today announced the launch of the SureSeq™ myPanel Myeloid Fusion MRD Panel, the first-to-market dedicated fusion MRD next-generation sequencing (NGS) panel for acute myeloid leukaemia (AML). This panel is now available publicly for customers to purchase and implement in their own workflows.
Genomic AML workflows traditionally cover only part of the genomic…
Celea has now contracted Qureight as the end-to-end imaging CRO for the phase 3 SURPASS-IPF trial, including Fibr8™ and four additional AI imaging models
Joint poster at CHEST 2026 presents analysis completed as part of Qureight’s work on Celea’s phase 2b ELEVATE-IPF trial, comparing enrolled patients’ baseline fibrosis severity with the PROFILE cohort, illustrating the approach behind Qureight’s Enrolled Cohort Reports
Cambridge, UK, 20 October 2026 – Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and…